IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

People with sickle cell disease often struggle with memory, focus, learning and problem solving, setting them back in ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

A PLAQUE celebrating the groundbreaking work of Dame Elizabeth Anionwu OM, the UK’s first sickle cell nurse counsellor, was ...

Madhya Pradesh has achieved 100 per cent target by screening 90,98,902 persons for the sickle cell disease so far, a ...

Statistics from the district health department indicate that in 2023, suspected cases of sickle cells stood at 1,456 and in ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Washington University researchers found that sickle cell disease causes brains to appear 14 years older than their actual age ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Madhya Pradesh has earned the distinction in the screening of sickle cell disease and distribution of sickle cell cards in ...